Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Adenosine Therapeutics awarded grant to develop drug eluting stents to prevent restenosis

Adenosine Therapeutics announced today the award of a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health.

6 Dec 2004

Sirolimus drug-coated stent causes less inflammation than bare metal stents

In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill.

11 Nov 2004

Early reports of thrombosis after insertion of drug-eluting stent

Authors of a research letter in this week’s issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy.

21 Oct 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004